Non-Alcoholic Fatty Liver Disease Pipeline Accelerates as 90+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
DelveInsight’s “Non-Alcoholic Fatty Liver Disease Pipeline Insight 2026” report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in the Non-Alcoholic Fatty Liver Disease pipeline landscape. It covers the Non Alcoholic Fatty Liver Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Non Alcoholic Fatty Liver Disease Pipeline @ https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight
Key Takeaways from the Non Alcoholic Fatty Liver Disease Pipeline Report
- On July 02, 2026- Inventiva Pharma initiated a Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage F2 or F3 and consists of 2 sequential parts – an initial double-blind placebo-controlled (DBPC) period (Part A) followed by a double-blind active treatment extension (ATE) period (Part B).
- On June 30, 2026- GlaxoSmithKline represented a phase 2b study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4). The study duration will be up to 76 weeks including the screening period. The treatment duration will be up to 52 weeks.
- On June 29, 2026- Novo Nordisk A/S highlighted a study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.
- On June 23, 2026- Haisco Pharmaceutical Group Co., Ltd. conducted a Phase 2b study to evaluate the efficacy and safety of once-daily, oral administration of 80 or 160 mg HSK31679 versus matching placebo in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis.
- On June 01, 2026- Madrigal Pharmaceuticals Inc. announced a Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or reduces fibrosis on liver biopsy and prevents progression to cirrhosis and/or advanced liver disease.
- DelveInsight’s Non Alcoholic Fatty Liver Disease pipeline report depicts a robust space with 90+ active players working to develop 100+ pipeline therapies for Non Alcoholic Fatty Liver Disease treatment.
- The leading Non Alcoholic Fatty Liver Disease Companies such as Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel, Inventiva Pharma, Galectin Therapeutics, AngioLab, MediciNova, AstraZeneca and others.
- Promising Non Alcoholic Fatty Liver Disease Pipeline Therapies such as Semaglutide, HEC96719, DA-1241, Sitagliptin, and others.
Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Non Alcoholic Fatty Liver Disease Treatment Drugs
NAFLD Overview
Non-alcoholic fatty liver disease is a broad term used to cover a spectrum of conditions that are characterized by evidence of hepatic steatosis on imaging or histology (macro-vesicular steatosis), and absence of secondary causes of hepatic steatosis such as significant alcohol consumption, chronic use of medications that can cause hepatic steatosis or hereditary disorders. The prevalence of NAFLD in western countries is around 20 to 30%. Obesity, diabetes, dyslipidemias, insulin resistance, and metabolic syndrome are known to be associated with the development of non-alcoholic fatty liver disease (NAFLD). A temporal association has also been shown between inorganic arsenic exposure and the development of NAFLD reflected by elevated alanine transferase (ALT). Due to its close association with metabolic syndrome, NAFLD correlates with cardiovascular risk factors, which also contributes to mortality in these patients in addition to end-stage liver cirrhosis and hepatocellular carcinoma.
Non Alcoholic Fatty Liver Disease Emerging Drugs Profile
- Lanifibranor: Inventiva Pharma
Lanifibranor is an orally-available small molecule that acts to induce anti-fibrotic, anti-inflammatory, and beneficial metabolic changes in the body by activating each of the three PPAR isoforms, known as PPARα, PPARδ, and PPARɣ. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARɣ and partial activation of PPARɣ. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Non-Alcoholic Fatty Liver Disease.
- ZED 1227: Dr. Falk Pharma GmbH
ZED 1227, is a synthetic peptidomimetic compound designed by Zedira scientists to specifically inhibit the enzymatic activity of human tissue transglutaminase (TG2). Dr. Falk Pharma has acquired the licensing rights to ZED1227 in Europe and several non-European countries and has assumed responsibility for pharmaceutical, preclinical, and clinical development of the new chemical entity towards a pharmaceutical product. By inhibiting TG2 in liver tissue, ZED1227 is expected to improve liver fibrosis in patients with NAFLD. Currently the drug is in Phase II stage of its clinical trial for the treatment of Non-Alcoholic Fatty Liver Disease.
- TVB-2640: Sagimet Biosciences
TVB-2640 is an oral, selective, first-in-class fatty acid synthase inhibitor that directly targets the primary drivers of NASH by reducing excess liver fat (steatosis), decreasing inflammation and blunting fibrosis. In addition to the FASCINATE-2 trial, denifanstat is being tested in a Phase III clinical trial for recurrent glioblastoma and a Phase II study for moderate to severe acne. Currently the drug is in Phase II stage of clinical trial for the treatment of Non-Alcoholic Fatty Liver Disease.
- ALS-L1023: AngioLab
ALS L1023 is a dried extract of ethyl acetate, prepared by activity-guided fractionation from Melissa leaf (lemon balm). The Angiogenesis Inhibitor ALS-L1023 from Lemon-Balm Leaves Attenuates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Regulating the Visceral Adipose-Tissue Function. Currently the drug is in Phase II stage of its clinical trial for the treatment of Non-Alcoholic Fatty Liver Disease.
- AZD9550: AstraZeneca
AZD9550 is a GLP-1R glucagon dual agonist small molecule which is in early development for the treatment of NASH (non-alcoholic steatohepatitis), a type of liver disease that commonly affects overweight and obese patients who have T2DM. Currently the drug is in Phase I/II stage of its clinical trial for the treatment of Non-Alcoholic Fatty Liver Disease.
The Non Alcoholic Fatty Liver Disease Pipeline Report Provides Insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Non Alcoholic Fatty Liver Disease with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non Alcoholic Fatty Liver Disease Treatment.
- Non Alcoholic Fatty Liver Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Non Alcoholic Fatty Liver Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non Alcoholic Fatty Liver Disease market
Explore groundbreaking therapies and clinical trials in the Non Alcoholic Fatty Liver Disease Pipeline @ New Non Alcoholic Fatty Liver Disease Drugs
Non Alcoholic Fatty Liver Disease Companies
Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel, Inventiva Pharma, Galectin Therapeutics, AngioLab, MediciNova, AstraZeneca, and others.
Non-Alcoholic Fatty Liver Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Non Alcoholic Fatty Liver Disease Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Unveil the future of Non Alcoholic Fatty Liver Disease Treatment @ Non Alcoholic Fatty Liver Disease Market Drivers and Barriers
Scope of the Non Alcoholic Fatty Liver Disease Pipeline Report
- Coverage- Global
- Non Alcoholic Fatty Liver Disease Companies- Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel, Inventiva Pharma, Galectin Therapeutics, AngioLab, MediciNova, AstraZeneca and others.
- Non Alcoholic Fatty Liver Disease Pipeline Therapies- Semaglutide, HEC96719, DA-1241, Sitagliptin, and others.
- Non Alcoholic Fatty Liver Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Non Alcoholic Fatty Liver Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Non Alcoholic Fatty Liver Disease Therapies and clinical trials @ Non Alcoholic Fatty Liver Disease Companies, Key Products and Unmet Needs
Table of Content
- Introduction
- Executive Summary
- Non-Alcoholic Fatty Liver Disease: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Non-Alcoholic Fatty Liver Disease – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Lanifibranor: Inventiva Pharma
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- ZED 1227: Dr. Falk Pharma GmbH
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- AZD9550: AstraZeneca
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name : Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Non-Alcoholic Fatty Liver Disease Key Companies
- Non-Alcoholic Fatty Liver Disease Key Products
- Non-Alcoholic Fatty Liver Disease – Unmet Needs
- Non-Alcoholic Fatty Liver Disease – Market Drivers and Barriers
- Non-Alcoholic Fatty Liver Disease – Future Perspectives and Conclusion
- Non-Alcoholic Fatty Liver Disease Analyst Views
- Non-Alcoholic Fatty Liver Disease Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight
